News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

European Commission (EC) Publishes Approval Of Octapharma AG’s Human Cell Line Recombinant FVIII (Nuwiq®) Across All Age Groups In Haemophilia A


8/6/2014 10:12:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LACHEN, Switzerland--(BUSINESS WIRE)--The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital factor VIII [FVIII] deficiency). Nuwiq® is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin. Nuwiq® is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor, both of which are potentially important properties in reducing FVIII inhibitor formation. The development of Nuwiq® aimed to address the challenges of inhibitor formation as well as the frequent infusions required for prophylaxis of bleeding.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES